Etanercept in combination with conventional disease-modifying antirheumatic drugs (DMARDs) in the treatment of rheumatoid arthritis patients intolerant to methotrexate

Modern Rheumatology

Volumn 22, Issue 1, 2012, Pages 100-108

  Koyama, Yoshinobu ^a   Shiraishi, Hirokazu ^a   Ohta, Toshiyuki ^a   Uchino, Ayumi ^a  

^a ASO IIZUKA HOSPITAL   (Japan)

Author keywords

Bucillamine; Combination therapy; Etanercept; Methotrexate; Salazosulfapyridine

Indexed keywords

BUCILLAMINE; ETANERCEPT; METHOTREXATE; SALAZOSULFAPYRIDINE; STEROID;

ADULT; ADVERSE DRUG REACTION; AGE; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DIZZINESS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEPATITIS C; HUMAN; KIDNEY DISEASE; LIVER DISEASE; LUNG INSUFFICIENCY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MONOTHERAPY; NEOPLASM; NEURITIS; OCULAR PRURITUS; PILOT STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SCIATIC NEURITIS; SCORING SYSTEM; STEROID THERAPY; SURVIVAL RATE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CYSTEINE; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULIN G; JOINTS; MALE; METHOTREXATE; MIDDLE AGED; PAIN MEASUREMENT; RECEPTORS, TUMOR NECROSIS FACTOR; RECOVERY OF FUNCTION; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SULFASALAZINE; TREATMENT FAILURE;

EID: 84861481520     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-011-0478-8     Document Type: Article

References (31)

1. Boers M. Understanding the window of opportunity concept in early rheumatoid arthritis. Arthritis Rheum. 2003;48:1771-4. (Pubitemid 36828668)
2. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62: 2569-81.
3. Ministry of Health, Labour and Welfare Study Group. Diagnosis manual and treatment guidelines under the principle of EBM (MHLW Study Group). Tokyo: Japan Rheumatism Foundation; 2004
4. American College of Rheumatology on Rheumatoid arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum. 2002;46:328-46.
5. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59:762-84. (Pubitemid 351847559)
6. Koike T, Harigai M, Inokuma S, Inoue K, Ishiguro N, Ryu J, et al. Post-marketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol. 2009;36:898-906.
7. Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67:189-94. (Pubitemid 351183307)
8. Harigai M. Is the combination of etanercept and methotrexate safe as a means of treating rheumatoid arthritis? Method for analysis of survey data from all etanercept-treated cases. Rheumatology. 2008;39:21-6.
9. Yoshio N, Nishimoto N. Criteria for selection among biological preparations. Clin Rheumatol Relat Res. 2008;20:13-8.
10. Maini R, St. Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. ATTRACT Study Group. Lancet. 1999;354:1932-9.
11. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000;343:1586-93. (Pubitemid 32162981)
12. Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. 2002;46:1443-50. (Pubitemid 34620189)
13. Emery P, Genovese MC, van Vollenhoven R, Sharp JT, Patra K, Sasso EH. Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis. J Rheumatol. 2009;36:1429-41.
14. Burmester GR, Mariette X, Montecucco C, Monteagudo-Sáez I, Malaise M, Tzioufas AG, et al. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis. 2007;66:732-9. (Pubitemid 46846691)
15. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet. 2004;363:675-81. (Pubitemid 38296553)
16. O'Dell JR, Petersen K, Leff R, Palmer W, Schned E, Blakely K, et al. Etanercept in combination with sulfasalazine, hydroxychloroquine, or gold in the treatment of rheumatoid arthritis. J Rheumatol. 2006;33:213-8. (Pubitemid 43209293)
17. Combe B, Codreanu C, Fiocco U, Gaubitz M, Geusens PP, Kvien TK, et al. Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study. Ann Rheum Dis. 2009;68:1146-52.
18. Iwamoto N, Kawakami A, Fujikawa K, Aramaki T, Kawashiri SY, Tamai M, et al. Prediction of DAS28-ESR remission at 6 months by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population. Mod Rheumatol. 2009;19:488-92.
19. Never-Zwart IH, van Riel PL, van de Putte LB, Gribnau FW, et al. A double-blind comparative study of sulphasalazine and hydroxychloroquine in rheumatoid arthritis: evidence of an earlier effect of sulphasalazine. Ann Rheum Dis. 1989;48:389-95. (Pubitemid 19130198)
20. Gadangi P, Longaker M, Naime D, Levin RI, Recht PA, Montesinos MC, et al. The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J Immunol. 1996;156:1937-41. (Pubitemid 26069328)
21. Shiokawa Y, Abe C, Warabi H, Abe S, Kageyama T, Kosaka S, et al. Clinical evaluation of SA96 on rheumatoid arthritis (in Japanese). ENSHOU. 1985;5:333-43.
22. Shiokawa Y, Ogawa N, Abe C, Kosaka S, Honma M, Akizuki M, et al. Efficacy official approval of SA96 on rheumatoid arthritis (in Japanese). I GAKU NO AYUMI. 1985;135:1116.
23. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-24. (Pubitemid 18091653)
24. Miyasaka N, Takeuchi T, Eguchi K. Guidelines for the proper use of etanercept in Japan. Mod Rheumatol. 2006;16:63-7.
25. Kameda H, Ueki Y, Saito K, et al. The comparison of efficacy and safety between etanercept (ETN) plus methotrexate (MTX) combination therapy and ETN monotherapy in MTX-refractory Japanese patients with rheumatoid arthritis: 24-week results from JESMR study. Ann Rheum Dis. 2008;67(Suppl II):184.
26. van Vollenhoven RF, Ernestam S, Harju A, Bratt J, Klareskog L. Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious. Arthritis Res Ther. 2003;5:R347-51.
27. Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis. 2009;68:1100-4.
28. Gochuico BR, Avila NA, Chow CK, Novero LJ, Wu HP, Ren P, et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med. 2008;168:159-66. (Pubitemid 351185882)
29. Santen Pharmaceutical Co., Ltd. Azulfidine EN tablets - summary of adverse reactions. 5th ed. Osaka: Santen Pharmaceutical Co., Ltd.; 2010
30. Santen Pharmaceutical Co., Ltd. Rimatil tablets - summary of adverse reactions. 5th ed. Osaka: Santen Pharmaceutical Co., Ltd.; 2010
31. Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010; 69:964-75.